In this model the drug has been shown to act at an additional level of the WNT pathway, i.e., by downregulating lymphoid enhancer-binding factor 1 (LEF1) expression, which is critical for regulating stemness via direct regulation of doublecortin-like kinase 1 (DCLK1)-B expression, whose levels correlate with CSCs and poor prognosis in CRC patients. Here, LEF1 is linked to colorectal carcinoma.